Fig. 10From: Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathwaysSummary of the mode of action exerted by Syndecan-1 in IBC progression. Syndecan-1 modulates expression and activation of the components of multiple signaling pathways including Notch, EGF/EGFR, and IL-6/STAT3/gp130. These changes have an impact on several features of the breast CSC phenotype, including CSC marker expression, and the formation of colonies and 3D spheroidsBack to article page